RT Journal Article
SR Electronic
T1 Vascular Inflammation in Lungs of Patients with Fatal Coronavirus Disease 2019 (COVID-19) Infection: Possible role for the NLRP3 inflammasome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.19.21253815
DO 10.1101/2021.03.19.21253815
A1 Oindrila Paul
A1 Jian Qin Tao
A1 Leslie Litzky
A1 Michael Feldman
A1 Kathleen Montone
A1 Chamith Rajapakse
A1 Christian Bermudez
A1 Shampa Chatterjee
YR 2021
UL http://medrxiv.org/content/early/2021/03/22/2021.03.19.21253815.abstract
AB Hyperinflammation is a key event that occurs with SARS-CoV-2 infection. In the lung, hyperinflammation leads to structural damage to tissue. To date, numerous lung histological studies have shown extensive alveolar damage, but there is scarce documentation of vascular inflammation in postmortem lung tissue. Here we document histopathological features and monitor the NLRP3 inflammasome in fatal cases of disease caused by SARS Cov2 (COVID-19). We posit that inflammasome formation along the vessel wall is a characteristic of lung inflammation that accompanies COVID-19 and that it is a probable candidate that drives amplification of inflammation post infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by NIH R56 HL139559.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This is approved by the University of Pennsylvania School of Medicine's IRB body, which works consistent with federal guidelines and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data is available with the coresponding author and can be shared with interested parties.